Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
12/06/20168:45AMBWOpdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response & Survival Rates in Recurrent Small ...
Objective response rate with Opdivo plus Yervoy was 25% and was 11% with Opdivo monotherapy; in the combination arm, three patients experienced a complete response Estimated two-year survival rate with the combination was 30% and was 17% with Opdivo monotherapy No new safety signals were observed with Opdivo and Opdivo... More...>>
12/06/20162:50AMDJNU.S. 'Disappointed' by Japan's Plan to Cut Drug Costs
TOKYO—The U.S. government has written to a senior aide of Japan's Prime Minister Shinzo Abe, calling on Tokyo to reconsider a plan that would allow more frequent pharmaceutical price cuts. The letter from Secretary of Commerce Penny Pritzker describes how the U.S. is "disappointed" by the Japanese... More...>>
12/05/20167:30PMBWSeattle Genetics & Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin)...
– Combination Data Showed 90 Percent Objective Response Rate and 62 Percent Complete Response Rate with an Acceptable Safety Profile in Pre-Transplant Relapsed or Refractory Classical Hodgkin Lymphoma Patients – – Data Support Continued Clinical Investigation of ADCETRIS and Opdivo Combination in Hodgkin Lymphoma... More...>>
12/05/20165:00AMBWEncouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up in First-line Advanced N...
In the pooled combination cohorts, median progression-free survival in patients with PD-L1 expression ≥1% was 12.7 months With longer follow-up, the Opdivo plus Yervoy combination had a safety profile consistent with previous reports of this study Bristol-Myers Squibb Company (NYSE:BMY) announced today updated findings... More...>>
11/30/20163:00PMBWBristol-Myers Squibb und Schauspieler Jack Huston rufen die Europäer auf, anlässlich des internationalen Lungenkrebs-Monats...
Die Kampagne The Next Lung Cancer A.C.T. veröffentlicht Umfrageergebnisse, laut denen Europäer erhebliche Wissenslücken aufweisen und übermässig sorglos mit dem Risiko umgehen. Europäer werden zu einem offenen, unterstützenden Dialog über Lungenkrebs ermutigt, etwa über Tweets unter dem Hashtag #LungenKrebsGespräch... More...>>
11/30/20163:00PMBWBristol-Myers Squibb et l’acteur Jack Huston marquent le mois de la sensibilisation au cancer du poumon en encourageant les...
La campagne The Next Lung Cancer A.C.T. souligne les résultats d’une enquête, révélant le fait que les Européens connaissent mal cette maladie et ne s’en inquiètent pas vraiment Les Européens sont encouragés à initier une conversation plus ouverte et utile sur le cancer du poumon au travers de publications... More...>>
11/30/20163:00PMBWBristol-Myers Squibb und Schauspieler Jack Huston rufen die Europäer auf, anlässlich des internationalen Lungenkrebs-Monats...
Die Kampagne The Next Lung Cancer A.C.T. veröffentlicht Umfrageergebnisse, laut denen Europäer erhebliche Wissenslücken aufweisen und übermäßig sorglos mit dem Risiko umgehen Europäer werden zu einem offenen, unterstützenden Dialog zum Thema Lungenkrebs aufgefordert, etwa über Tweets unter dem Hashtag #LungenKrebsGespräch... More...>>
11/30/20169:54AMBWBristol-Myers Squibb to Take Part at the Citi 2016 Global Healthcare Conference
Bristol-Myers Squibb Company (NYSE: BMY) will take part in the Citi 2016 Global Healthcare Conference on Wednesday, December 7, 2016, in New York. Giovanni Caforio, M.D., chief executive officer, and Francis Cuss, MB, BChir, FRCP, chief scientific officer, will make formal remarks and answer questions about the company... More...>>
11/22/20163:00PMBWEuropean Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or...
First and only PD-1 inhibitor approved for a hematologic malignancy in the European Union Approval based on an overall response rate, as demonstrated by data from an integrated analysis of two trials, CheckMate -205 and CheckMate -039 This milestone marks the sixth EU approval for Opdivo in four distinct cancer types in... More...>>
11/16/20165:13PMBWBristol-Myers Squibb Presents New Data at IASLC 17th World Conference on Lung Cancer Underscoring Progress & Leadership in Br...
CheckMate -012 data for Opdivo monotherapy and in combination with Yervoy in first-line treatment of advanced non-small cell lung cancer, to be presented Response and survival data from CheckMate -032 in second-line small cell lung cancer, also among presentations Bristol-Myers Squibb Company (NYSE:BMY) today announced... More...>>
11/16/20165:20AMBWBristol-Myers Squibb et Enterome SA annoncent une collaboration en Immuno-Oncologie dédiée à la découverte de biomarqueur...
Bristol-Myers Squibb (NYSE:BMY) et Enterome SA (Enterome), acteur majeur du développement de médicaments et de diagnostics issus du microbiote intestinal, annoncent la signature d’un accord stratégique de collaboration dédié à l’Immuno-Oncologie pour la recherche et le développement de cibles thérapeutiques... More...>>
11/16/20164:04AMPRNUSBristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Ta...
Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Targets and Bioactive Molecules PR Newswire PARIS and NEW YORK, November 16, 2016 PARIS and NEW YORK, November 16, 2016 /PRNewswire/ -- Bristol-Myers Squibb (NYSE: BMY) and Enterome SA (Enterome... More...>>
11/16/20164:04AMPRNUSBristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Ta...
Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Targets and Bioactive Molecules PR Newswire PARIS and NEW YORK, November 16, 2016 PARIS and NEW YORK, November 16, 2016 /PRNewswire/ -- Bristol-Myers Squibb (NYSE: BMY) and Enterome SA (Enterome... More...>>
11/16/20163:00AMBWBristol-Myers Squibb & Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets...
Bristol-Myers Squibb Company (NYSE:BMY) and Enterome, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and... More...>>
11/14/20166:59AMBWBristol-Myers Squibb Showcases Rheumatoid Arthritis & Immunoscience Commitment with Depth of Research at 2016 American Colleg...
Presentation of real-world data demonstrating that biomarkers of poor prognosis may help identify rheumatoid arthritis (RA) patient populations at risk for rapidly progressing disease New ORENCIA® (abatacept) data in RA and related autoimmune diseases featured in multiple presentations Bristol-Myers Squibb Company (NYSE:BMY... More...>>
11/12/201611:30AMBWOpdivo (nivolumab) & Yervoy (ipilimumab) Regimen Shows Promising Efficacy & Safety in Previously Treated Patients With Advanc...
Data from CheckMate -032 showed a confirmed objective response rate of 38.5% in previously treated metastatic urothelial carcinoma patients who received the Opdivo 1 mg/kg and Yervoy 3 mg/kg regimen No new safety signals identified with the Opdivo and Yervoy regimen Results support further development of Opdivo plus Yervoy... More...>>
11/12/201611:15AMBWInterim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (nivolumab) in Patients Wit...
Objective response rate (ORR) was 24% in 29 evaluable patients and increased in inflamed (PD-L1 positive) tumors, with ORR of 41% in patients with ≥1% PD-L1 expression No significant added toxicity over Opdivo monotherapy observed First disclosure of data for clinical activity with the combination of anti-KIR and anti-PD-1... More...>>
11/12/201610:40AMBWPhase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic & Solid Tumors Suggest Increased Antitumor Effect in...
Objective response rate was 50% in 46 evaluable melanoma patients, and disease control rate was 70% In melanoma patients, antitumor activity seen in both PD-L1 expressors and non-expressors, with ORR of 50% in those with ≥1% PD-L1 expression and 47% in patients with <1% PD-L1 expression No significant added toxicity... More...>>
11/10/20165:00PMBWBristol-Myers Squibb’s Opdivo® (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall...
Opdivo is the first and only Immuno-Oncology treatment proven in a Phase 3 trial to significantly extend overall survival for patients with recurrent or metastatic squamous cell head and neck cancer who had been previously treated with platinum-based therapy1 NCCN guidelines recently updated to include treatment with Opdivo... More...>>
11/10/20164:15PMBWBristol-Myers Squibb to Showcase New Data Spanning Rheumatoid Arthritis & Other Autoimmune Diseases at 2016 American College ...
Analyses explore ORENCIA® (abatacept) treatment and disease burden among patients with poor prognostic factors for rapidly progressive rheumatoid arthritis (RA) New abatacept data from Phase 3 psoriatic arthritis and juvenile idiopathic arthritis studies Pipeline Phase 2 and 3 data highlight Bristol-Myers Squibb’s commitment... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20161206 14:12:04